2020 HET JAAR VAN LODOCO2 - CVGK
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
2020 Het Jaar van LoDoCo2
Research Publication
“ Authors Name”
Article Name
JOURNAL NAME ,
Volume XX, Issue XX, Date , Page Ref
https://doi.org/XXX/yyj/zzzz
6528 Enrolled
91.3% Tolerated open label therapy
Randomized
5522 Followed for a median of 29 months (12-64 months)
90.3% in each arm continued their trial medication
3.4% in each arm ceased due to perceived effects
5521
5521 Close-out
Began on December 4, 2019; Ended February 17, 2020
99.9% Final, end point status known
LoDoCo 2
The LoDoCo2 Trial
Colchicine for 2o Prevention of Cardiovascular Disease
An Australian-Dutch Collaboration
1606
1616
1642
Continuous Use of Low Dose Colchicine is Safe Long-term daily doses of up to 2mg/d is FDA approved [FMF] 5-10% experience mild early GI effects - dose related1 Myo-, BM toxicity & Death limited to cases of over dose It has no detrimental effects on renal or hepatic function2 Serious drug interactions are rare – Clarithromycin3 1 98% tolerate 0.25mg/day 2 Used in advanced renal failure [20% renal excretion] and cirrhosis 3 Nexium 7 Colchicine has had a bad wrap because of the way we were taught to use it ‘You must rapidly over-dose patients to make them run so they could walk’
When Clinicians take their Ideas from Bench to Bedside
it Requires a Leap of Faith
… they need to go forward aware of uncertainties but
‘in the confident hope of a miracle’*
* Admiral Martin de Bertendona,
Commander of the [Spanish Armada] Levant squadron
Expressing doubts about the chances of success of the invasion of England
FILMPJE Mark Nidorf en andere AUS onderzoekers
STATUS INCLUSIE FOLLOW-UP
Aanloop….
Mei 2015
Sept 2008 Nov 2012 Start samenwerking
Aus: start inclusie Publicatie & Australië & Nederland
LoDoCo presentatie
LoDoCo Feb 2014
Aus: Start inclusie
LoDoCo2
‘08 ‘09 ‘10 ‘11 ‘12 ‘13 ‘14 ‘15 ‘16STATUS INCLUSIE FOLLOW-UP
“Vrijwel iedereen kan meedoen!”
Dixit: Aernoud Fiolet
ca. 75% van patiënten met stabiel
coronairlijden is geschiktGloriosa superba “Tour de LoDoCo” drug rediscovery in the spotlight
Human uses
Gloriosa superba
The alkaloid-rich plant has long been used as a traditional medicine in many cultures.
It has been used in the treatment of:
• gout • typhus • smallpox
• infertility • itching • sexually transmitted diseases
• open wounds • leprosy • many types of internal parasites
• snakebite • bruises • anthelmintic
• ulcer • sprains • used as a laxative
• arthritis • hemorrhoids • used as an alexiteric
• cholera • cancer • the sap is used to
• colic • impotence treat acne and head lice
• kidney problems • Nocturnal emission • it may cause abortion
• in parts of India, extracts of the
rhizome are applied topically
during childbirth to reduce labor
pain.STATUS INCLUSIE FOLLOW-UP
The journey
Inclusie & Follow-UpSTATUS INCLUSIE FOLLOW-UP
The journey
Inclusie & Follow-Up
Over
Flits Audits in Meppel en Perth
Ontbijt in Barcelona
De Fiets van uw FiscusESC Barcelona 28 Augustus 2017, 07.30 uur (< 24 uur post CANTOS)
6528 Enrolled
91.3% Tolerated open label therapy
Randomized
5522 Followed for a median of 29 months (12-64 months)
90.3% in each arm continued their trial medication
3.4% in each arm ceased due to perceived effects
5521
5521 Close-out
Began on December 4, 2019; Ended February 17, 2020
99.9% Final, end point status knownTrots op TeamWork in alle Geledingen
FILMPJE vandaag gemaakt met Mark Nidorf
You can also read
